Eli Lilly and Company logo

Eli Lilly and Company (LLY)

Market Open
27 Feb, 17:47
NYSE NYSE
$
1,032. 32
+10.3
+1.01%
$
970.55B Market Cap
104.2 P/E Ratio
6% Div Yield
934,278 Volume
6.64 Eps
$ 1,022.02
Previous Close
Day Range
1,017.36 1,034.24
Year Range
623.78 1,133.95
Want to track LLY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
LLY earnings report is expected in 61 days (29 Apr 2026)
Eli Lilly (LLY) Stock Declines While Market Improves: Some Information for Investors

Eli Lilly (LLY) Stock Declines While Market Improves: Some Information for Investors

Eli Lilly (LLY) closed the most recent trading day at $797.48, moving -0.3% from the previous trading session.

Zacks | 1 year ago
Lilly asks US government to pause drug price negotiation program, Bloomberg News reports

Lilly asks US government to pause drug price negotiation program, Bloomberg News reports

Eli Lilly has asked the U.S. government to pause the new law that allows Medicare to negotiate prices for its costliest prescription drugs, Bloomberg News reported on Monday, citing Lilly Chief Executive Dave Ricks.

Reuters | 1 year ago
Eli Lilly CEO expects new weight loss pill to be approved next year

Eli Lilly CEO expects new weight loss pill to be approved next year

Eli Lilly expects its experimental weight loss pill, orforglipron, to be approved as soon as early next year, CEO David Ricks told Bloomberg. Eli Lilly and Novo Nordisk, which dominate the market with their obesity injections Zepbound and Wegovy, are both looking to develop next-generation versions.

Cnbc | 1 year ago
Eli Lilly to buy cancer drug developer Scorpion Therapeutics for $2.5 bln

Eli Lilly to buy cancer drug developer Scorpion Therapeutics for $2.5 bln

Eli Lilly said on Monday it would acquire cancer therapy developer Scorpion Therapeutics for $2.5 billion in cash.

Reuters | 1 year ago
Lilly sues two medical spas over copycat weight-loss drugs

Lilly sues two medical spas over copycat weight-loss drugs

Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound.

Reuters | 1 year ago
Eli Lilly: Still Much Room To Ride The Weight-Loss Wave

Eli Lilly: Still Much Room To Ride The Weight-Loss Wave

Eli Lilly: Still Much Room To Ride The Weight-Loss Wave

Seekingalpha | 1 year ago
Andreessen Horowitz, Eli Lilly to launch $500 million venture fund

Andreessen Horowitz, Eli Lilly to launch $500 million venture fund

Venture capital firm Andreessen Horowitz said on Friday it was working with Eli Lilly to launch a $500 million venture fund that will be fully funded by the U.S. drugmaker.

Reuters | 1 year ago
Eli Lilly (LLY) Vs Novo Nordisk (NVO): Which is the Best Weight Loss Stock for 2025?

Eli Lilly (LLY) Vs Novo Nordisk (NVO): Which is the Best Weight Loss Stock for 2025?

Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly (LLY) and Novo Nordisk (NVO) stock.

Zacks | 1 year ago
LLY Falls Around 14% in 3 Months: How to Play the Stock

LLY Falls Around 14% in 3 Months: How to Play the Stock

Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth prospects.

Zacks | 1 year ago
Top pharmaceutical stocks to buy in 2025

Top pharmaceutical stocks to buy in 2025

Pharmaceutical stocks represent an interesting prospect — while it is incredibly tough to separate the wheat from the chaff, picking a winner early on is more or less a ticket to outsized returns.

Finbold | 1 year ago
Why the Market Dipped But Eli Lilly (LLY) Gained Today

Why the Market Dipped But Eli Lilly (LLY) Gained Today

In the latest trading session, Eli Lilly (LLY) closed at $773.29, marking a +1.07% move from the previous day.

Zacks | 1 year ago
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks | 1 year ago
Loading...
Load More